AI Business recently caught up with Adam Hanina, CEO of AiCure.

AiCure’s patented artificial intelligence platform visually confirms medication ingestion on mobile devices. The company is working with large and mid-sized biopharmaceutical companies to improve the quality and speed of drug development, and with academic partners, brand teams and payers to ensure that patients benefit from the same treatment efficacy that was achieved during the clinical trial process.

Adam is a passionate advocate for the use of artificial intelligence as a population health tool and has spoken extensively on the topic of healthcare innovation. He holds 18 patents and has acted as a subject-matter expert on medication adherence technologies for the NIH.

Adam will be sharing his AI in healthcare expertise at The AI Summit in San Francisco on 28-29 September, where he will deliver his practical keynote on ‘Real-world applications of AI in healthcare’, including using AI to develop better drugs and better treatment for patients through verification of drug ingestion, and discussing how the use of AI can drive better health outcomes and greater efficiencies.



Adam Hanina of AiCure


Adam points out that AI is already having a profound impact on business models in many sectors, but is particularly focused on his own sector:

“In healthcare, AI has the potential to lead to a far greater democratization of care, in terms of cost, quality, and access. The introduction of AI into diagnostics, monitoring, and clinical trial design has the potential to improve treatments and the health of millions on a global scale. Major pharmaceutical companies are already relying on AiCure’s platforms to provide access to patient data that was previously inaccessible, giving them insight into real-time patient behaviour and offering them a more precise understanding of how a drug works.


Many AI thought-leaders cite human attitude as a barrier to AI adoption. Interestingly, Adam is actually impressed by society’s adaptability and its embracing of AI:

We are seeing both incremental and transformative shifts in the rate of adoption of innovation in business practice. However, the rapid accumulation and integration of data and processes into standard business practices from incremental shifts are helping to bring about the more profound and transformative changes that typically take longer to come to fruition. As incredible as some of these changes may be, I find it amazing how quickly society is able to recalibrate and turn its perception of science fiction into mainstream expectation.

Instead, Adam believes the biggest challenge to adoption is the balance between the AI use case and the associated return on investment. He expands on this and outlines further obstacles:

“The balance between use case and ROI is critical to ensuring sustainability of the service with the upfront engineering effort needed to develop the solution. Estimating both sides of this equation can be complex and needs to be considered carefully.

“On the technical side, while the deployment of AI solutions in real world settings is not trivial, most engineering challenges will be overcome. The progress in computational power will allow for more sophisticated techniques to be deployed broadly and many challenges can be tackled by limiting the scope of the problem.

“Finally, most businesses today are probably not looking at their data architecture in a way that will optimize AI approaches. That could be a lost opportunity in many cases”.


Discussion turns to AiCure’s own applications of AI. Adam explains their key proposition, which combines deep learning, computer vision, and predictive analytics to visually confirm medication ingestion and then intervene with a patient accordingly:

“The platform provides a medication reminder to the patient, confirms their identity, the medication based on shape, colour and markings, and then the act of ingestion. Billions of data points around patient behaviour according to demographics, disease state, age, etc. can be used to refine our understanding of how well treatments are working, which patients need most help, and how to ensure patients stay out of the hospital.


From a broader strategic standpoint, Adam says that AiCure’s focus is on building and deploying advanced AI technologies to optimize patient behaviour and medication adherence. He reflects upon the company’s beginnings as he looks towards its future:

“I founded the company in 2010 to revolutionize patient monitoring with the ultimate goal of keeping the patients we love alive longer and out of the hospital. By 2020, we are working towards demonstrating that we have saved over 100,000 lives and accelerated new medications into the marketplace by over 100,000 days”.


Having started a business with AI at its heart – indeed in its name – Adam shares his thoughts on what is required by an existing enterprise to embrace and adopt AI technologies:

“The first step is to define an extremely clear business case for adoption and articulate the value to the client ideally through data.  If you can do that, you’ve overcome a major obstacle. The second requirement is to identify leadership within the organization that has the sway and desire to deploy new technologies”.


Adam describes healthcare as a “traditionally very labour-intensive field”. But what does this mean for the impact of AI?

AI has the potential to transform accessibility, quality, and continuity of care for patients around the world. Ultimately this will have a ripple effect in terms of the quality of medicines that reach the market and the quality of care that patients receive.

He goes further to assert that “healthcare is ripe for AI adoption”:

“Not only is this a data-rich environment that urgently needs efficiency and quality improvements, but the motivation to change is there. At AiCure, we believe that there is no greater mission than the one dedicated to saving lives through artificial intelligence”.


At The AI Summit in San Francisco on 28-29 September, Adam Hanina will deliver his keynote on  on ‘Real-world applications of AI in healthcare’.

He will be joined at the event by fellow CxOs from the world’s leading enterprises and the most exciting AI software developers, all gathering to explore the huge opportunity that AI presents the healthcare industry, and many more industries besides.

To find out more, and to register to attend the event, visit:


AI Summit San Fran print screen


For the latest news and conversations about AI in business, follow us on Twitterjoin our community on LinkedIn and like us on Facebook

Feature image credit: